378 related articles for article (PubMed ID: 8901663)
41. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
42. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.
Spratt JC; Goddard J; Patel N; Strachan FE; Rankin AJ; Webb DJ
Br J Pharmacol; 2001 Oct; 134(3):648-54. PubMed ID: 11588120
[TBL] [Abstract][Full Text] [Related]
43. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
Rafnsson A; Shemyakin A; Pernow J
Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
[TBL] [Abstract][Full Text] [Related]
44. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF.
Warner TD; Allcock GH; Corder R; Vane JR
Br J Pharmacol; 1993 Oct; 110(2):777-82. PubMed ID: 8242251
[TBL] [Abstract][Full Text] [Related]
45. Effect of endothelin-1 (1-31) on the renal resistance vessels.
Ozawa Y; Hasegawa T; Tsuchiya K; Yoshizumi M; Tamaki T
J Med Invest; 2003 Feb; 50(1-2):87-94. PubMed ID: 12630573
[TBL] [Abstract][Full Text] [Related]
46. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
47. Typical endothelin ETA receptors mediate atypical endothelin-1-induced contractions in sheep isolated tracheal smooth muscle.
Henry PJ; King SH
J Pharmacol Exp Ther; 1999 Jun; 289(3):1385-90. PubMed ID: 10336530
[TBL] [Abstract][Full Text] [Related]
48. Paradoxically enhanced endothelin-B receptor-mediated vasoconstriction in conscious old monkeys.
Asai K; Kudej RK; Takagi G; Kudej AB; Natividad F; Shen YT; Vatner DE; Vatner SF
Circulation; 2001 May; 103(19):2382-6. PubMed ID: 11352888
[TBL] [Abstract][Full Text] [Related]
49. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart.
Kobayashi T; Miyauchi T; Sakai S; Kobayashi M; Yamaguchi I; Goto K; Sugishita Y
Am J Physiol; 1999 Apr; 276(4):H1197-206. PubMed ID: 10199843
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-1beta attenuates endothelin B receptor-mediated airway contractions in a murine in vitro model of asthma: roles of endothelin converting enzyme and mitogen-activated protein kinase pathways.
Zhang Y; Adner M; Cardell LO
Clin Exp Allergy; 2004 Sep; 34(9):1480-7. PubMed ID: 15347384
[TBL] [Abstract][Full Text] [Related]
51. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition.
Böhm F; Beltran E; Pernow J
J Intern Med; 2005 Mar; 257(3):263-71. PubMed ID: 15715683
[TBL] [Abstract][Full Text] [Related]
52. Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature.
Moreland S; McMullen D; Abboa-Offei B; Seymour A
Br J Pharmacol; 1994 Jun; 112(2):704-8. PubMed ID: 8075891
[TBL] [Abstract][Full Text] [Related]
53. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure.
Zolk O; Quattek J; Sitzler G; Schrader T; Nickenig G; Schnabel P; Shimada K; Takahashi M; Böhm M
Circulation; 1999 Apr; 99(16):2118-23. PubMed ID: 10217651
[TBL] [Abstract][Full Text] [Related]
54. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
[TBL] [Abstract][Full Text] [Related]
55. Ca2+ signalling by endothelin receptors in rat and human cultured airway smooth muscle cells.
Maxwell MJ; Goldie RG; Henry PJ
Br J Pharmacol; 1998 Dec; 125(8):1768-78. PubMed ID: 9886769
[TBL] [Abstract][Full Text] [Related]
56. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
57. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
58. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.
Maguire JJ; Kuc RE; O'Reilly G; Davenport AP
Br J Pharmacol; 1994 Sep; 113(1):49-54. PubMed ID: 7812631
[TBL] [Abstract][Full Text] [Related]
59. ET-1-induced bronchoconstriction is mediated via ETB receptor in mice.
Nagase T; Aoki T; Oka T; Fukuchi Y; Ouchi Y
J Appl Physiol (1985); 1997 Jul; 83(1):46-51. PubMed ID: 9216943
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure.
Ohnishi M; Wada A; Tsutamoto T; Fukai D; Kinoshita M
Cardiovasc Res; 1998 Sep; 39(3):617-24. PubMed ID: 9861304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
